Table_1_Individualization of Hematopoietic Stem Cell Transplantation Using Alpha/Beta T-Cell Depletion.pdf
Allogeneic hematopoietic stem cell transplantation (HSCT) is associated with several potentially lethal complications. Higher levels of CD3+ T-cells in the graft have been associated with increased risk of graft-versus-host disease (GVHD), but also beneficial graft-versus-leukemia effect and reduced infections. To tackle post-transplant complications, donor lymphocyte infusions have been used but with an increased risk of GVHD. To reduce this risk, we performed depletion of αβ T-cells and treated 12 patients post-HSCT suffering from infections and/or poor immune reconstitution. The αβ T-cell depleted cell products were characterized by flow cytometry. The median log depletion of αβ T-cells was −4.3 and the median yield of γδ T-cells was 73.5%. The median CD34+ cell dose was 4.4 × 106/kg. All 12 patients were alive 3 months after infusion and after 1 year, two patients had died. No infusion-related side effects were reported and no severe acute GVHD (grade III-IV) developed in any patient post-infusion. Overall, 3 months after infusion 11 out of 12 patients had increased levels of platelets and/or granulocytes. In conclusion, we describe the use of αβ T-cell depleted products as stem cell boosters with encouraging results.
History
References
- https://doi.org//10.1111/j.1365-2141.2009.07886.x
- https://doi.org//10.1016/j.bbmt.2011.05.001
- https://doi.org//10.3324/haematol.2013.087338
- https://doi.org//10.1038/sj.bmt.1703248
- https://doi.org//10.1086/597123
- https://doi.org//10.1038/nri3384
- https://doi.org//10.1182/blood-2010-01-255166
- https://doi.org//10.1038/sj.bmt.1705650
- https://doi.org//10.1016/j.bcmd.2007.07.001
- https://doi.org//10.1172/JCI81229
- https://doi.org//10.1155/2014/578741
- https://doi.org//10.1182/blood-2014-03-563817
- https://doi.org//10.1016/j.jcyt.2013.05.014
- https://doi.org//10.1182/blood-2017-04-779769
- https://doi.org//10.1080/14653240701644000
- https://doi.org//10.1111/trf.14579
- https://doi.org//10.1038/sj.bmt.1701290
- https://doi.org//10.1111/j.1365-2141.2006.06333.x
- https://doi.org//10.1016/j.bbmt.2014.05.016
- https://doi.org//10.1080/2162402X.2016.1216291
- https://doi.org//10.1016/j.bbmt.2014.09.027
- https://doi.org//10.1084/jem.20041851
- https://doi.org//10.1182/blood-2008-01-136713
- https://doi.org//10.1086/314568
- https://doi.org//10.1111/j.1432-2277.2010.01095.x
- https://doi.org//10.1038/ni.3686
- https://doi.org//10.1016/j.bbmt.2016.09.006
- https://doi.org//10.3389/fimmu.2016.00188
- https://doi.org//10.1371/journal.pone.0154737
Usage metrics
Read the peer-reviewed publication
Categories
- Transplantation Immunology
- Tumour Immunology
- Immunology not elsewhere classified
- Immunology
- Veterinary Immunology
- Animal Immunology
- Genetic Immunology
- Applied Immunology (incl. Antibody Engineering, Xenotransplantation and T-cell Therapies)
- Autoimmunity
- Cellular Immunology
- Humoural Immunology and Immunochemistry
- Immunogenetics (incl. Genetic Immunology)
- Innate Immunity